PINNED
PINNED
Endotoxin testing milestone reached with European Pharmacopoeia’s animal shift
The quality control (QC) standards publication sets animal-free bacterial endotoxins testing (BET) as the new norm in Europe.
List view / Grid view
News
Real-world evidence showed superiority of Novartis’ Gilenya® to reduce MS relapse rates compared to interferons or glatiramer acetate
3 October 2013 | By Novartis
"Controlling relapses and preventing disability are key treatment goals for patients with MS..."
US Appeals Court lifts temporary injunction against Hanmi’s 505(b)2 NDA esomeprazole strontium product
2 October 2013 | By AstraZeneca
AstraZeneca announced that the US Court of Appeals for the Federal Circuit (CAFC) lifted a temporary injunction against the US launch of Hanmi's 505(b)2 NDA esomeprazole strontium product...
US Appeals Court lifts temporary injunction against Hanmi’s 505(b)2 NDA esomeprazole strontium product
2 October 2013 | By AstraZeneca
Hanmi’s launch would be at risk of owing AstraZeneca patent-infringement damages...
New data analyses show significant clinical and MRI improvements with PLEGRIDY™ (Peginterferon Beta-1a)
1 October 2013 | By biogen idec
Analyses reinforce efficacy of PLEGRIDY, further supporting a potential new treatment option for people with multiple sclerosis...
AstraZeneca welcomes new arrivals as Alderley Park BioHub expands
1 October 2013 | By AstraZeneca
The growth of the BioHub complements the work of the Alderley Park taskforce to capitalise and build on the existing local bioscience network and expertise...
Amgen successfully completes Onyx pharmaceuticals tender offer
1 October 2013 | By Amgen
"Amgen's acquisition of Onyx fits perfectly with our commitment to advancing medicines for cancer patients around the world..."
VISTAKON® Division Of Johnson & Johnson Vision Care, Inc. sponsors free eye exam event for World Sight Day
1 October 2013 | By Johnson & Johnson
“Everyone needs a complete eye exam because that’s how you are more likely to prevent blindness and eye disease..."
Newly published phase III exploratory analysis suggests investigational oral laquinimod for multiple sclerosis may reduce brain damage caused by neurodegeneration
1 October 2013 | By Teva Pharmaceutical Industries Ltd
"This Phase III sub-study was pre-planned to explore the ability of laquinimod to act on mechanisms leading to irreversible brain tissue damage..."
Roche inaugurates translational and Clinical Research Center at the Alexandria Center for life science in New York City
1 October 2013 | By Roche
Leading scientists join together to discuss breakthrough research that addresses serious medical needs...
Novartis to reveal landmark Phase III results from specialty dermatology portfolio at upcoming EADV 2013 congress
1 October 2013 | By Novartis
Data from head-to-head pivotal study showing secukinumab (AIN457) superiority to Enbrel®* (etanercept) in moderate-to-severe plaque psoriasis to be revealed...
Interim data for Merck’s MK-3475, an investigational Anti-PD-1 immunotherapy, in previously treated patients with non-small cell Lung Cancer to be presented at 15th World Conference on lung cancer
1 October 2013 | By Merck
An abstract (# 2416) published today summarized preliminary findings from 38 patients with NSCLC treated with MK-3475...
Bristol-Myers Squibb to present range of new hepatitis C data at the 2013 American Association for the study of liver diseases (AASLD) annual meeting
1 October 2013 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) announced today that 16 abstracts have been accepted for presentation at The Liver Meeting® 2013...
GlaxoSmithKline reaches agreement with Aspen to divest thrombosis brands and related manufacturing site for £0.7 billion
30 September 2013 | By GlaxoSmithKline
GlaxoSmithKline (LSE:GSK) today announced it has reached agreement to sell its thrombosis brands, Arixtra® and Fraxiparine®, and the Notre-Dame de Bondeville (NDB)...
Amgen presents new data from phase 3 study of Talimogene Laherparepvec in patients with metastatic melanoma
30 September 2013 | By Amgen
"These results further support the primary analysis reported at ASCO which demonstrated a statistically significant durable response rate..."
Data show Roche’s new subcutaneous form of Herceptin is preferred by patients and could save resources in Europe’s hospitals
30 September 2013 | By Roche
Use of new Herceptin formulation reduced the time needed for pharmacists and doctors to treat patients...
